N. Vardakis - Concepedia

Author

N. Vardakis

University Hospital of Heraklion

Also Known As

N Vardakis, N. Vardakis, Nikos Vardakis

Publications

891

Citations

H-Index

Concepts

All Affiliations

University Hospital of Heraklion University of Crete IASO General Hospital National and Kapodistrian University of Athens Sotiria General Hospital

About

N. Vardakis is an author at University Hospital of Heraklion specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	436
2	Pharmacology	6	6	266
3	Pathology	4	4	151
4	Health Sciences	2	2	32
5	Immunology	1	1	50

N. Vardakis

Publications

853

Citations

H-Index

Page 1

	Year	Citations
Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial Vassilis Georgoulias, Charalambos Kouroussis, N. Androulakis, Journal of Clinical Oncology	1999	128
Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial John Souglakos, D. Mavroudis, Stylianos Kakolyris, Journal of Clinical Oncology	2002	119
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy John Souglakos, A. Kalykaki, L. Vamvakas, Annals of Oncology OncologyPhase Ii TrialGastrointestinal OncologyMedicineOxaliplatin-based Chemotherapy	2006	63
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial Zenia Saridaki, N. Androulakis, N. Vardakis, British Journal of Cancer	2012	56
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study N. Androulakis, Charalambos Kouroussis, S. Kakolyris, Annals of Oncology OncologyNon-small-cell Lung CancerSalvage TreatmentDocetaxel-based ChemotherapyPharmacology	1998	54
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study Eleni‐Kyriaki Vetsika, Soultana Christou, Dora Hatzidaki, Annals of Oncology Clinical OutcomeOncologyReverse VaccinologyMedicineImmunology	2011	50
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial John Souglakos, Konstantinos Syrigos, Anna Potamianou, Annals of Oncology OncologyGastrointestinal OncologyMedicineFirst-line TreatmentSurgery	2004	48
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel–gemcitabine chemotherapy Athanasios Pallis, Sofia Agelaki, S. Kakolyris, Lung Cancer MedicineFront-line Docetaxel–gemcitabine ChemotherapyPrognostic FactorMetronomic TherapyPathology	2008	46
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study Stylianos Kakolyris, E. Papadakis, Xanthi Tsiafaki, Lung Cancer Second-line TreatmentOncologyRhg-csf SupportMedicinePharmacotherapy	2001	35
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors D. Mavroudis, Periklis Pappas, Ch. Kouroussis, Annals of Oncology OncologyMedicineMetronomic TherapyPharmacokinetic StudyAdvanced Solid Tumors	2003	35

Page 1